Beryl Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Beryl Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-714,084	Closed	-$2.71M	–	72
2020 Q1	$2.71M	Buy	+714,084	New	+$3.08M	0.57%	18

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Beryl Capital Management's PGNX Position: Q2 2020 in Review

Beryl Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 714,084 shares — an estimated $2.71M sold.

Beryl Capital Management first reported a position in PGNX in Q1 2020 and held it in 1 quarter. The position peaked at $2.71M in Q1 2020. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Beryl Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Beryl Capital Management sold 714,084 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $2.71M.
Beryl Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2020 and held it in 1 quarter.
Beryl Capital Management's Progenics Pharmaceuticals Inc position peaked at $2.71M in Q1 2020.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Beryl Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.